This document addresses immune response algorithmic tests for oncologic disease management. At least one test, Immunoscore^® (Veracyte Inc.), which has been investigated for management of colon cancer, has been  commercially available. The test, which is performed on tissue samples, assesses immune response at the tumor site.

Position Statement

Investigational and Not Medically Necessary:

Oncologic immune biomarker tests are considered investigational and not medically necessary for all indications.